Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Title: CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and ...

Whether it's a class project, social campaign, or personal expression, North Penn students use tools such as AI video generation tools, Free AI Face Swap, and GTA Style Art Generator to create ...

Poster #3 : Advancing buntanetap: comparative pharmacokinetic characterization of the original semi-crystalline with the novel crystalline form in animals and humans.

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

Poster #4: Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases. Presenter: Matthew Peterson, Ph.D., Senior Clinical Scientist. The AAIC ...

Aquestive Therapeutics, Inc. announced that it will present results from studies on its investigational product, Anaphylm™ (epinephrine) Sublingual Film, at the CFAAR Food Allergy Summit in ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin ...

Key Findings from the Poster Presentations: Results from participants receiving oral, once-daily mavorixafor monotherapy showed that mavorixafor durably increased mean ANC from baseline over the 6 ...